Natera stock: At EUR 359.70, Natera stock rises 3.24 percent versus Xetra close

Published on 10/19/2026 at 16:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock costs EUR 359.70 on October 19, 2026, up 3.24 percent versus Xetra close. Second-quarter revenue reached USD 752.75 million in 2026.

Price movement and coming results

Natera's euro quotation rose on October 19, 2026.
Second-quarter revenue reached USD 752.75 million in 2026.
Natera stock costs EUR 359.70 at Lang & Schwarz on October 19, 2026 at 4:38 p.m. CEST, 3.24 percent above the Xetra close of October 16, 2026.
Natera is expected to report third-quarter results on November 5, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

At EUR 359.70, Natera stock was 3.24 percent above the Xetra close of October 16, 2026 on October 19, 2026. The move places the diagnostics company in a stronger short-term position, while its latest reported quarter gives the market a concrete operating reference. Second-quarter revenue reached USD 752.75 million, according to MarketBeat. Natera was trading at EUR 359.70 at Lang & Schwarz on October 19, 2026 at 4:38 p.m. CEST, up 3.24 percent versus the Xetra close.

Revenue sets the next marker

The second quarter ended June 30, 2026 with revenue of USD 752.75 million and a net loss attributable to common shareholders of USD 66.97 million. Diluted earnings per share were negative USD 0.47 for the quarter. Operating cash flow was USD 54.79 million, giving investors a more detailed view than revenue alone.

Natera's investor-relations page describes a portfolio spanning women's health, oncology and organ health, including Panorama, Signatera and Prospera. The company says its testing platform combines cell-free DNA analysis, molecular biology, bioinformatics software and artificial intelligence in a range of clinical applications, as outlined by Natera.

The price sits below its yearly high

The Nasdaq quotation was USD 403.99 at 10:48 a.m. ET on October 19, 2026. That was 7.64 percent below the 52-week high of USD 437.41 and well above the 52-week low of USD 181.00. The same quotation carried a market capitalization of USD 58.2 billion, while volume stood at 235,056 shares against an average of 1,456,898.

Valuation and November results

Natera's trailing price-to-earnings ratio was negative 296.27 on October 19, 2026, reflecting its reported loss rather than a positive earnings base. The next scheduled reporting date is November 5, 2026, after the market close, with the conference call set for 4:30 p.m. ET, according to MarketBeat.

Comparison with peers

Natera: plus 3.24 percent, P/E negative 296.27, market capitalization USD 58.2 billion

Illumina (Nasdaq, USD): minus 0.17 percent, P/E 48.90, market capitalization USD 39.6 billion

Market context: Market report S&P 500.

Natera was trading at EUR 359.70 at Lang & Schwarz on October 19, 2026 at 4:38 p.m. CEST, 3.24 percent above the Xetra close of October 16, 2026 at EUR 348.40. The further course of trading is shown by the continuously updated real-time quote of Natera stock.